Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to collect safety information on rabeprazole 10 mg and
20 mg in the treatment of gastroesophageal reflux disease (GERD) in children aged 12 to 16
years. The secondary objectives are to assess the efficacy of rabeprazole on the improvement
of the symptoms of GERD and to explore the relationship of symptom relief to dose received,
based on symptom frequency and severity, antacid use, and quality of life (QOL) measures.